Eyepoint Pharmaceuticals Inc (EYPT)
$4.58
$0.08
(1.78%)
As on 01-Sep-2026 16:13EDT
Market cap
$376 Mln
Revenue (TTM)
$3 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.5 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
11.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.7
-
Face value
--
-
Shares outstanding
83,841,298
10 Years Aggregate
CFO
$-243.45 Mln
EBITDA
$-349.74 Mln
Net Profit
$-475.05 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eyepoint Pharmaceuticals Inc (EYPT)
| -74.9 | -62.6 | -66.3 | -60.4 | -22.7 | -16.0 | -19.2 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Eyepoint Pharmaceuticals Inc (EYPT)
| 145.2 | -67.5 | 560.3 | -71.4 | 86.0 | -57.5 | -18.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eyepoint Pharmaceuticals Inc (EYPT)
|
4.6 | 375.6 | 2.8 | -306.6 | -10,672.1 | -129.8 | -- | 2.4 |
| 17.7 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 202.8 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.6 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 113.4 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.2 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 23.9 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.3 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 66.9 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 132.1 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Eyepoint Pharmaceuticals Inc (EYPT)
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug... delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts. Read more
-
President, CEO & Director
Dr. Jay S. Duker M.D.
-
President, CEO & Director
Dr. Jay S. Duker M.D.
-
Headquarters
Watertown, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Eyepoint Pharmaceuticals Inc (EYPT)
What is the current share price of Eyepoint Pharmaceuticals Inc (EYPT) Today?
The share price of Eyepoint Pharmaceuticals Inc (EYPT) is $4.58 (NASDAQ) as of 01-Sep-2026 16:13 EDT. Eyepoint Pharmaceuticals Inc (EYPT) has given a return of -22.68% in the last 3 years.
What is the current PB & PE ratio of Eyepoint Pharmaceuticals Inc (EYPT)?
Since, TTM earnings of Eyepoint Pharmaceuticals Inc (EYPT) is negative, P/E ratio is not available.
The P/B ratio of Eyepoint Pharmaceuticals Inc (EYPT) is 2.39 times as on 28-Aug-2026, a 69 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-6.54 |
4.96 |
2024 |
-3.67 |
1.43 |
2023 |
-13.77 |
3.66 |
2022 |
-1.28 |
1.36 |
2021 |
-6.85 |
2.17 |
What is the 52 Week High and Low of Eyepoint Pharmaceuticals Inc (EYPT)?
The 52-week high and low of Eyepoint Pharmaceuticals Inc (EYPT) are Rs 19.11 and Rs 3.95 as of 02-Sep-2026.
What is the market cap of Eyepoint Pharmaceuticals Inc (EYPT)?
Eyepoint Pharmaceuticals Inc (EYPT) has a market capitalisation of $ 376 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Eyepoint Pharmaceuticals Inc (EYPT)?
Before investing in Eyepoint Pharmaceuticals Inc (EYPT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.